Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey – The Lancet Invited commentary: CoronaVac: more data for regulators and policy makers   Commentary on Twitter NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against […]

The post RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection. appeared first on Links Medicus.